Literature DB >> 32980877

Vericiguat in worsening heart failure: agonising over, or celebrating, agonism in the VICTORIA trial.

Ninian N Lang1, Stephen J H Dobbin1, Mark C Petrie1.   

Abstract

Entities:  

Keywords:  Heart failure; Nitric oxide; Vericiguat; sGC

Year:  2020        PMID： 32980877      PMCID： PMC7519883          DOI： 10.1093/cvr/cvaa247

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN： 0008-6363            Impact factor:   10.787


× No keyword cloud information.
  13 in total

Review 1.  Role of guanylate cyclase modulators in decompensated heart failure.

Authors:  Veselin Mitrovic; Adrian F Hernandez; Markus Meyer; Mihai Gheorghiade
Journal:  Heart Fail Rev       Date:  2009-12       Impact factor: 4.214

2.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.

Authors:  John J V McMurray; Scott D Solomon; Silvio E Inzucchi; Lars Køber; Mikhail N Kosiborod; Felipe A Martinez; Piotr Ponikowski; Marc S Sabatine; Inder S Anand; Jan Bělohlávek; Michael Böhm; Chern-En Chiang; Vijay K Chopra; Rudolf A de Boer; Akshay S Desai; Mirta Diez; Jaroslaw Drozdz; Andrej Dukát; Junbo Ge; Jonathan G Howlett; Tzvetana Katova; Masafumi Kitakaze; Charlotta E A Ljungman; Béla Merkely; Jose C Nicolau; Eileen O'Meara; Mark C Petrie; Pham N Vinh; Morten Schou; Sergey Tereshchenko; Subodh Verma; Claes Held; David L DeMets; Kieran F Docherty; Pardeep S Jhund; Olof Bengtsson; Mikaela Sjöstrand; Anna-Maria Langkilde
Journal:  N Engl J Med       Date:  2019-09-19       Impact factor: 91.245

3.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur J Heart Fail       Date:  2016-05-20       Impact factor: 15.534

4.  Comparing the Benefit Of Novel Therapies Across Clinical Trials: Insights from the VICTORIA Trial.

Authors:  Javed Butler; Kevin J Anstrom; Paul W Armstrong
Journal:  Circulation       Date:  2020-03-28       Impact factor: 29.690

Review 5.  Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease.

Authors:  Johannes-Peter Stasch; Pál Pacher; Oleg V Evgenov
Journal:  Circulation       Date:  2011-05-24       Impact factor: 29.690

6.  Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure.

Authors:  Markus Follmann; Jens Ackerstaff; Gorden Redlich; Frank Wunder; Dieter Lang; Armin Kern; Peter Fey; Nils Griebenow; Walter Kroh; Eva-Maria Becker-Pelster; Axel Kretschmer; Volker Geiss; Volkhart Li; Alexander Straub; Joachim Mittendorf; Rolf Jautelat; Hartmut Schirok; Karl-Heinz Schlemmer; Klemens Lustig; Michael Gerisch; Andreas Knorr; Hanna Tinel; Thomas Mondritzki; Hubert Trübel; Peter Sandner; Johannes-Peter Stasch
Journal:  J Med Chem       Date:  2017-06-12       Impact factor: 7.446

7.  Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.

Authors:  Scott D Solomon; John J V McMurray; Inder S Anand; Junbo Ge; Carolyn S P Lam; Aldo P Maggioni; Felipe Martinez; Milton Packer; Marc A Pfeffer; Burkert Pieske; Margaret M Redfield; Jean L Rouleau; Dirk J van Veldhuisen; Faiez Zannad; Michael R Zile; Akshay S Desai; Brian Claggett; Pardeep S Jhund; Sergey A Boytsov; Josep Comin-Colet; John Cleland; Hans-Dirk Düngen; Eva Goncalvesova; Tzvetana Katova; Jose F Kerr Saraiva; Małgorzata Lelonek; Bela Merkely; Michele Senni; Sanjiv J Shah; Jingmin Zhou; Adel R Rizkala; Jianjian Gong; Victor C Shi; Martin P Lefkowitz
Journal:  N Engl J Med       Date:  2019-09-01       Impact factor: 91.245

8.  Angiotensin-neprilysin inhibition versus enalapril in heart failure.

Authors:  John J V McMurray; Milton Packer; Akshay S Desai; Jianjian Gong; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile
Journal:  N Engl J Med       Date:  2014-08-30       Impact factor: 91.245

9.  Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.

Authors:  Paul W Armstrong; Burkert Pieske; Kevin J Anstrom; Justin Ezekowitz; Adrian F Hernandez; Javed Butler; Carolyn S P Lam; Piotr Ponikowski; Adriaan A Voors; Gang Jia; Steven E McNulty; Mahesh J Patel; Lothar Roessig; Joerg Koglin; Christopher M O'Connor
Journal:  N Engl J Med       Date:  2020-03-28       Impact factor: 91.245

10.  cGMP: a unique 2nd messenger molecule - recent developments in cGMP research and development.

Authors:  Andreas Friebe; Peter Sandner; Achim Schmidtko
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-12-18       Impact factor: 3.000
View more
  2 in total

Review 1.  A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021.

Authors:  Gizem Kayki-Mutlu; Zinnet Sevval Aksoyalp; Leszek Wojnowski; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-05-11       Impact factor: 3.195

2.  Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial.

Authors:  Carolyn S P Lam; Hillary Mulder; Yuri Lopatin; Jose B Vazquez-Tanus; David Siu; Justin Ezekowitz; Burkert Pieske; Christopher M O'Connor; Lothar Roessig; Mahesh J Patel; Kevin J Anstrom; Adrian F Hernandez; Paul W Armstrong
Journal:  J Am Heart Assoc       Date:  2021-11-06       Impact factor: 5.501
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.